Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...
Ovaries01:26

Ovaries

The ovaries are roughly the size of almonds and measure approximately 2 to 3 centimeters in length. These paired structures are situated within the pelvic region and are anchored by the mesovarium—a peritoneal extension that also connects them to the wider structure of the broad ligament. The support system extends to the suspensory ligament, housing blood and lymphatic vessels. In addition, the ovarian ligament tethers the ovaries to the uterus.
On the ovarian surface, a layer of cuboidal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Feasibility, safety and outcomes of contrast-free cardiac resynchronisation therapy device implantation: a retrospective cohort comparison.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2026
Same author

Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292).

ESMO open·2025
Same author

Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Study protocol of an exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA) - a randomized controlled trial.

BMC cancer·2024
Same author

ICG mapping of postoperative lymphatic leakage in the groin: a video article and literature review.

Facts, views & vision in ObGyn·2024

Related Experiment Video

Updated: Jul 10, 2026

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

[Epithelial ovarian cancer].

F Hilpert1, G Krause, L Venhoff

  • 1Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Kiel. fhilpert@email.uni-kiel.de

Therapeutische Umschau. Revue Therapeutique
|October 24, 2007
PubMed
Summary

Ovarian cancer (OC) has high mortality due to late diagnosis. Treatment strategies differ for early-stage, advanced, and recurrent OC, with platinum-based chemotherapy being key for improving outcomes in platinum-sensitive cases.

More Related Videos

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
05:42

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

Published on: January 26, 2024

Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

Related Experiment Videos

Last Updated: Jul 10, 2026

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
05:42

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

Published on: January 26, 2024

Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Cancer Research

Context:

  • Ovarian cancer (OC) presents a significant challenge due to late-stage diagnosis in most patients, leading to high mortality rates.
  • Current prognostic factors include FIGO stage and residual disease post-surgery; early-stage OC has a favorable prognosis with appropriate treatment.
  • Advanced-stage OC management focuses on maximal cytoreduction and platinum-based chemotherapy, though recurrence is common.

Purpose:

  • To outline the current understanding and management strategies for ovarian cancer across different stages.
  • To differentiate treatment approaches and prognoses for early-stage, advanced-stage, and recurrent ovarian cancer.
  • To emphasize the importance of surgical staging, cytoreduction, and platinum-based chemotherapy in ovarian cancer treatment.

Summary:

  • Early-stage OC (FIGO Ia-II) requires complete surgical resection and adjuvant platinum-based chemotherapy for a ~90% survival rate.
  • Advanced-stage OC (FIGO IIb-IV) necessitates maximal cytoreduction followed by six cycles of carboplatin/paclitaxel.
  • Recurrent OC prognosis depends on platinum sensitivity; platinum-sensitive disease shows better response rates (30-50%) to platinum-based combination therapies than platinum-refractory disease (<20% response).

Impact:

  • Highlights the critical role of surgical completeness and platinum-based chemotherapy in improving ovarian cancer patient survival.
  • Underscores the palliative approach for recurrent disease, focusing on quality of life and symptom management.
  • Informs clinical decision-making regarding treatment intensity and surgical intervention for recurrent platinum-sensitive ovarian cancer.